Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDO-Guided vs Conventional Therapy for Advanced Abdominal Tumors
NCT05378048Phase 2Withdrawn
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in abdominal neoplasms (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Tumor progression-free survival at 12 months. Planned start Jul 2022; status: withdrawn.
02
Conditions
abdominal neoplasms
Beyond the preview
Go deeper on NCT05378048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378048.